Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • SVR Trial
Long-Term Reality of Single-Ventricle Reconstruction: Shunt Choice, Tricuspid Regurgitation, and the Burden of Global Morbidity
Posted inCardiology news Pediatrics

Long-Term Reality of Single-Ventricle Reconstruction: Shunt Choice, Tricuspid Regurgitation, and the Burden of Global Morbidity

Posted by MedXY By MedXY 03/11/2026
A 16-year follow-up of the SVR trial reveals that while shunt types show similar long-term outcomes overall, pre-existing tricuspid regurgitation significantly impacts survival with RVPAS, amid a staggering 87% rate of major morbidity.
Read More
  • ACOG Endorses Updated 2026 Cervical Cancer Screening Guidelines: Key Changes and Implications
  • Combination Therapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors Reduces Liver and Cardiovascular Risks in MASLD and Type 2 Diabetes
  • CD16+ γδ T Cells: A Novel Player in HBV Viral Control Through Antibody-Dependent Cytotoxicity
  • Clonal Lymphocyte Expansions and JAK-STAT Mutations Drive Refractory Celiac Disease
  • EVT Shows Superior Outcomes in Anterior Cerebral Artery Occlusion Stroke: Insights from the ORIENTAL-MeVO Registry
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in